Ohio native and former presidential candidate Vivek Ramaswamy is expected to announce a 2026 bid for governor in a campaign that will likely showcase his business background as well as his anti-“woke” and pro-Trump views.

He’s worth somewhere in the neighborhood of $1 billion. So what exactly is Ramaswamy’s business background and how did he get rich so young?

Here’s a quick overview:

Born in 1985 to Indian immigrant parents (his father was a General Electric engineer and attorney, his mother a psychiatrist), Ramaswamy grew up in the Cincinnati suburb of Evendale. He attended St. Xavier High School, graduating as valedictorian in 2003.

Studying biology at Harvard, he also co-founded a business, StudentBusinesses.com, a tech startup that connected budding entrepreneurs with professional resources via the internet. The business was later sold to the Kauffman Foundation, a nonprofit that fosters entrepreneurs and education.

Vivek Ramaswamy (right) pictured in 2003 in The Enquirer with Ryan Fischer, of Holmes High School, when the two won $20,000 scholarships from Coca-Cola.

After graduating from Harvard, Ramaswamy joined QVT Financial, a New York-based investment advisory firm and hedge fund manager. Some QVT investors would later fund his future business ventures.

He also pursued a law degree at Yale University, graduating in 2013 (Vice President JD Vance was a classmate and graduated the same year).

His work at QVT involved investing in biotech companies, which led to his interest in the development of new prescription drugs.

Trump-friendly billionaires: Elon Musk vastly outranks all other ‘superbillionaires’ in new report on richest people

Ramaswamy’s biotech expertise led to an idea for a new business venture.

Pharmaceutical companies had more patents on developing drugs than they could develop, win regulatory approval for, and bring to market. Large drug companies would fund what they hoped would be their next big blockbuster drug, while other potential medicines would languish.

In 2014, he founded Roivant Sciences to buy or license promising drugs that weren’t a priority for their owners. Roivant would then take over the development process for the potential future medicine. The company organized its developing drugs into subsidiary companies that could be spun off into separate ventures or be sold.

In 2015, Ramaswamy cashed out a piece of his Roivant stake, accounting for the majority of his nearly $37.1 million in capital gains on his tax return.

Former Republican presidential candidate Vivek Ramaswamy endorses former President Donald Trump's reelection campaign in Atkinson, N.H., on Jan. 16, 2024.
Former Republican presidential candidate Vivek Ramaswamy endorses former President Donald Trump’s reelection campaign in Atkinson, N.H., on Jan. 16, 2024.

A potential Alzheimer’s Disease drug, called intepirdine, was the main drug under development at Axovant, a Roivant subsidiary that the company spun off in a 2015 initial public offering. The stock nearly doubled in price on the first day of trading, making the company worth nearly $3 billion.

Share.
2025 © Network Today. All Rights Reserved.